Market Cap 13.29M
Revenue (ttm) 0.00
Net Income (ttm) -33.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 646,700
Avg Vol 122,938
Day's Range N/A - N/A
Shares Out 5.34M
Stochastic %K 44%
Beta 1.74
Analysts Strong Sell
Price Target $21.00

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 300 5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
BG_BULL
BG_BULL May. 8 at 8:13 PM
$MBRX It seems to me that with every news, someone tries to sell and push the price down. I add. I believe it will jump very sharply at some point 💪
1 · Reply
ezMoney001
ezMoney001 May. 8 at 1:16 PM
$MBRX UnF@k$N - believable !!
0 · Reply
focafoca99
focafoca99 May. 8 at 1:06 PM
$MBRX obtained a new Hong Kong patent for its liposomal Annamycin formulation, extending global exclusivity through 2040. https://www.rapidticker.com/news/mbrx-moleculin-biotech-secures-strategic-additional-d0c428
0 · Reply
focafoca99
focafoca99 May. 8 at 1:01 PM
$MBRX gained a new Hong Kong patent covering its proprietary liposomal Annamycin method. https://www.rapidticker.com/news/mbrx-sec-filing-7c8c7f
0 · Reply
Stock_Catcher
Stock_Catcher May. 8 at 12:45 PM
$MBRX Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
0 · Reply
IVALTE
IVALTE May. 7 at 4:34 PM
$MBRX humo
0 · Reply
ONLYPHARMS
ONLYPHARMS May. 7 at 9:37 AM
$MBRX no earnings date from the company yet? cash running out soon. next few months is extreamly important
0 · Reply
IVALTE
IVALTE May. 7 at 9:12 AM
$MBRX humo
0 · Reply
IVALTE
IVALTE May. 7 at 3:38 AM
$MBRX hdlgp
0 · Reply
IVALTE
IVALTE May. 5 at 9:07 PM
$MBRX venden humo
0 · Reply
Latest News on MBRX
Moleculin Biotech management to meet with Maxim

2026-04-02T15:10:34.000Z - 5 weeks ago

Moleculin Biotech management to meet with Maxim


Moleculin Biotech Transcript: The 38th Annual Roth Conference

Mar 24, 2026, 3:00 PM EDT - 6 weeks ago

Moleculin Biotech Transcript: The 38th Annual Roth Conference


Moleculin Biotech sees cash runway into 3Q26

2026-03-19T12:41:00.000Z - 7 weeks ago

Moleculin Biotech sees cash runway into 3Q26


Moleculin to Present at 38th Annual ROTH Conference

Mar 17, 2026, 9:05 AM EDT - 7 weeks ago

Moleculin to Present at 38th Annual ROTH Conference


Moleculin Biotech announces launch of CEO Corner platform

2026-02-13T13:35:29.000Z - 3 months ago

Moleculin Biotech announces launch of CEO Corner platform


Moleculin Biotech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:20 PM EST - 3 months ago

Moleculin Biotech Transcript: Corporate Connect Webinar Series


Moleculin Announces New Annamycin Collaboration in Brain Tumors

Dec 8, 2025, 8:21 AM EST - 5 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors


Moleculin Biotech trading halted, news pending

2025-11-28T21:50:14.000Z - 5 months ago

Moleculin Biotech trading halted, news pending


Moleculin Announces Reverse Stock Split

Nov 26, 2025, 9:00 AM EST - 5 months ago

Moleculin Announces Reverse Stock Split


Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 9 months ago

Moleculin Issues New Positive AML Overall Survival Data:


Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 11 months ago

Moleculin Announces $5.9 Million Public Offering


Moleculin Biotech Transcript: Study Update

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Transcript: Study Update


Moleculin Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Earnings Call Transcript: Q1 2025


BG_BULL
BG_BULL May. 8 at 8:13 PM
$MBRX It seems to me that with every news, someone tries to sell and push the price down. I add. I believe it will jump very sharply at some point 💪
1 · Reply
ezMoney001
ezMoney001 May. 8 at 1:16 PM
$MBRX UnF@k$N - believable !!
0 · Reply
focafoca99
focafoca99 May. 8 at 1:06 PM
$MBRX obtained a new Hong Kong patent for its liposomal Annamycin formulation, extending global exclusivity through 2040. https://www.rapidticker.com/news/mbrx-moleculin-biotech-secures-strategic-additional-d0c428
0 · Reply
focafoca99
focafoca99 May. 8 at 1:01 PM
$MBRX gained a new Hong Kong patent covering its proprietary liposomal Annamycin method. https://www.rapidticker.com/news/mbrx-sec-filing-7c8c7f
0 · Reply
Stock_Catcher
Stock_Catcher May. 8 at 12:45 PM
$MBRX Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
0 · Reply
IVALTE
IVALTE May. 7 at 4:34 PM
$MBRX humo
0 · Reply
ONLYPHARMS
ONLYPHARMS May. 7 at 9:37 AM
$MBRX no earnings date from the company yet? cash running out soon. next few months is extreamly important
0 · Reply
IVALTE
IVALTE May. 7 at 9:12 AM
$MBRX humo
0 · Reply
IVALTE
IVALTE May. 7 at 3:38 AM
$MBRX hdlgp
0 · Reply
IVALTE
IVALTE May. 5 at 9:07 PM
$MBRX venden humo
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 10:45 PM
$MBRX RSI: 49.09, MACD: 0.0107 Vol: 0.08, MA20: 2.52, MA50: 2.35 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
0 · Reply
captainjoerg
captainjoerg May. 4 at 2:19 PM
$CNSP look too at the stock of their prior partner $MBRX
1 · Reply
captainjoerg
captainjoerg May. 4 at 2:10 PM
$MBRX +3.3% now? Rocket will be fuelled :D
0 · Reply
captainjoerg
captainjoerg May. 4 at 1:56 PM
$MBRX today MBRX´s old partner $CNSP makes +300%. Maybe $MBRX the next?
0 · Reply
captainjoerg
captainjoerg May. 4 at 1:56 PM
$MBRX today MBRX´s old partner $CNSP makes +300%. Maybe %MBRX the next?
0 · Reply
IVALTE
IVALTE Apr. 30 at 2:30 PM
0 · Reply
Merlintrader
Merlintrader Apr. 26 at 6:30 PM
$MBRX Three Biotech Microcaps Heating Up: $MBRX, $CRBP, and $NTHI — Catalysts Are Approaching https://www.merlintrader.com/three-biotech-microcaps-heating-up-mbrx-crbp-nthi/
0 · Reply
LFC4EVER
LFC4EVER Apr. 26 at 5:44 PM
$MBRX Once it gets discovered, will fly.... No doubt! Avg PT is $21... tic toc...
0 · Reply
LFC4EVER
LFC4EVER Apr. 23 at 6:20 PM
$MBRX Taking off soon... BULLISH... 🔥💥🚀
0 · Reply
focafoca99
focafoca99 Apr. 23 at 6:01 PM
$MBRX presented AACR preclinical data showing Annamycin extended survival by more than 60% in metastatic pancreatic-cancer models https://www.rapidticker.com/news/mbrx-sec-filing-df867e
0 · Reply
ezMoney001
ezMoney001 Apr. 23 at 2:57 PM
$MBRX mmm what's that color i see today... on the same day as news ??? Wow !!
0 · Reply